4 Feb
2021

SCOTUS’ denial of certiorari in Idenix v Gilead poses especially difficult IP questions for universities and small biotechs

Recent Federal Circuit case law on section 112(a) has raised serious doubts over the enforceability of US genus claims, leaving life sciences rights holders in a quandary.

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth